Oxford, UK – 7 February 2019: Oxford Biomedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, has been informed that as part of a company-wide portfolio review, Sanofi intends to seek a new partner for Oxford Biomedica’s outlicensed ophthalmology gene therapies, SAR422459… Read More
Oxford, UK – 06 December 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, notes an announcement today by Axovant Sciences regarding feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) concerning AXO-Lenti-PD for patients with… Read More
Oxford, UK – 01 December 2018: Oxford Biomedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA and JULIET pivotal trials in children and young adult patients with relapsed or… Read More
Oxford, UK – 23 November 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces the formation of a new digital framework initiative to streamline the production of next-generation medicines. Oxford Biomedica will invest a total of £4 million, supported by… Read More
Oxford, UK – 25 October 2018: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, notes that its partner, Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, has announced the successful dosing of the first patient… Read More
London, UK – 5 October 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces additional details of its strategic alliance with Orchard Therapeutics, as disclosed in the public filing by Orchard Therapeutics on a Form F-1 Registration Statement ahead… Read More
Lentiviral vector bioprocessing market expected to grow to $800m by 2026 Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector bioprocessing market (excluding milestones and royalties) Oxford, UK – 13 September 2018: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford… Read More
Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018. FINANCIAL HIGHLIGHTSGross income growth of 118% to £36.0 million (H1 2017: £15.7 million)… Read More
London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of paediatric… Read More
Oxford, UK – 6 August 2018: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into a process development collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a… Read More
London, UK – 29 June 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval… Read More
~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below) Oxford, UK– 06 June 2018: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into an exclusive worldwide licensing… Read More